In vitro study of r-hirudin permeability through membranes of different haemodialysers

被引:22
作者
Bucha, E [1 ]
Kreml, R [1 ]
Nowak, G [1 ]
机构
[1] Univ Jena, Max Planck Gesell, Res Unit Pharmacol Haemostaseol, D-6900 Jena, Germany
关键词
haemodialysis; membrane permeability; r-hirudin;
D O I
10.1093/ndt/14.12.2922
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. After introducing the specific thrombin inhibitor recombinant hirudin (r-hirudin) into clinical practice in cases of heparin-induced thrombocytopenia (HIT, type II) the possibility of its use as an anticoagulant during haemodialysis treatment in HIT II patients is being discussed more frequently. On the one hand, the efficient, safe and routine use of r-hirudin during haemodialyses, including the maintenance of a therapeutic blood level, presupposes that no r-hirudin will leave the circulation by passing through the dialyser membrane. On the other hand, it is important to have dialysers whose permeability to r-hirudin allows its efficient removal from the human body because, to date, no antidote is commercially available in cases of dangerously high blood concentrations of r-hirudin. Methods. An in vitro circulation model was used to study the r-hirudin permeability of some low- and high-flux dialysers. As r-hirudin-containing vehicles, both albumin-containing saline solution and bovine blood were circulated in the blood space of the system for 2 h. Transmembrane r-hirudin passage was tested by measuring r-hirudin concentration both in the blood and dialysate space fluids using the ecarin clotting time (ECT). Results. Low-flux dialysers with membranes made from polysulfone or regenerated cellulose proved to be almost impermeable to r-hirudin. In contrast, other low-flux membranes were partly permeable to r-hirudin (e.g. Hemophan) or even almost completely permeable (e.g. cellulose acetate). All high-flux dialysers tested were permeable to r-hirudin. Conclusions. Only low-flux dialysers with polysulfone or regenerated cellulose membranes proved to be suitable for r-hirudin use in routine haemodialysis therapy. Other low-flux, and all high-flux, capillaries are permeable to r-hirudin and offer the possibility of lowering toxic r-hirudin concentrations after overdosing.
引用
收藏
页码:2922 / 2926
页数:5
相关论文
共 19 条
[1]  
Becker, 1994, J Thromb Thrombolysis, V1, P7
[2]  
Bloom DMS, 1996, THROMB HAEMOSTASIS, V76, P480
[3]   HIRUDIN IN HEMODIALYSIS [J].
BUCHA, E ;
MARKWARDT, F ;
NOWAK, G .
THROMBOSIS RESEARCH, 1990, 60 (06) :445-455
[4]   Clinical trials of recombinant hirudin in acute coronary syndromes [J].
Challapalli, R ;
Lefkovits, J ;
Topol, EJ .
CORONARY ARTERY DISEASE, 1996, 7 (06) :429-437
[5]  
Kakkar VV, 1996, CARDIOVASC RISK FACT, V6, P148
[6]   CLINICO-PHARMACOLOGICAL STUDIES WITH RECOMBINANT HIRUDIN [J].
MARKWARDT, F ;
NOWAK, G ;
STURZEBECHER, J ;
VOGEL, G .
THROMBOSIS RESEARCH, 1988, 52 (05) :393-400
[7]   THE DEVELOPMENT OF HIRUDIN AS AN ANTITHROMBOTIC DRUG [J].
MARKWARDT, F .
THROMBOSIS RESEARCH, 1994, 74 (01) :1-23
[8]   PHARMACOLOGY OF R-HIRUDIN IN RENAL IMPAIRMENT [J].
NOWAK, G ;
BUCHA, E ;
GOOCK, T ;
THIELER, H ;
MARKWARDT, F .
THROMBOSIS RESEARCH, 1992, 66 (06) :707-715
[9]   Quantitative determination of hirudin in blood and body fluids [J].
Nowak, G ;
Bucha, E .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1996, 22 (02) :197-202
[10]  
Nowak G, 1997, WIEN KLIN WOCHENSCHR, V109, P354